Director,Cancer Therapeutics Program; Medical Director, Center for Uro-Oncology Research Excellence (CURE) - Cedars-Sinai-Cancer
Joined April 2013
- Tweets 675
- Following 193
- Followers 650
- Likes 161
168 Photos and videos
Edwin Posadas, MD retweeted
Appreciate the⚠️caution voiced by #PCWG4 @AarmstrongDuke et al.@JCO_ASCO
#PSMA imaging in #ProstateCancer is not🚫ready for prime time to determine treatment failure (distinct from imaging PD) in clinical practice
PSMA may harm pts if it leads to stopping a tx too quickly
1
8
15
6,033
Great way to cap off #colorectalcancer awareness month hosting our @CSCancerCenter #CRC research social w/Dr. Alessio Pigazzi @EdwinPosadasMD for a productive exchange of ideas, networking & future collabs w/PhDs & MDs in #CRC research @AGangiMD @fdossa @SGrivennikov @SekiEki
4
10
952
Edwin Posadas, MD retweeted
The @thenci past meets the present @asco #GU26
Dr. Melissa Abel @melissaabel20 discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh @harpreet_md
The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time @theNCI
6
17
2,291
Edwin Posadas, MD retweeted
Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday
3
27
69
4,156
Dr Joshua Watson showing novel biology associated with #livermetastases in #prostatecancer! Proud of his exciting work #GU26
2
80
Edwin Posadas, MD retweeted
As we get ready for the update on the overall survival in #BRCAAway trial @asco #GU26
It is worth noting the small number of patients that’s crossed over.
In that context this data has its limits in comparing combination vs sequence in #ProstateCancer
25 Jan 2024
Here is the crossover data from #BRCAAway trial.
Small numbers in study accentuated by limited crossover. This highlights in this setting this is really a question of #PFS2 not just #PFS
#ProstateCancer @asco #GU24
2
7
441
@AmarUKishan POSEIDON meta-analysis of 6 PhIII RCTs on hormonal therapy (HT) after post-op RT (PORT) in localized #Prostatecancer ➡️ no OS benefit w/HT to PORT & no significant interaction b/t duration of HT & this effect (p-interaction 0.25) for PSA<0.5
#GU26 @OncoAlert
9
11
378
Edwin Posadas, MD retweeted
#BRCAaway OS data presented by Dr. Maha Hussein
#GU26 @asco
Launched prior to large phase 3s in #ProstateCancer Cancer
Provocative data but as Dr Hussein acknowledges small numbers in cross over (8 patients) limits ability to truly understand sequencing vs combo
2
4
8
569
Edwin Posadas, MD retweeted
Dr Evan Yu takes stage @asco #GU26 to discuss #Peace3 & #BRCAaway
Too often superlatives are thrown around on this app…
But do yourself a favor. Watch this whole discussion. One of the more thoughtful takes on modern clinical trial dilemmas in #ProstateCancer
Thank you Dr Yu
8
17
1,393
Edwin Posadas, MD retweeted
27 Aug 2025
It’s always a beautiful day when you can go to clinic and observe a successful #bicalutamide withdrawal maneuver
📉
Yes… even in 2025 🙂
Sometimes less is more in #ProstateCancer (#nmCRPC)
Flashback to Dr. Evan Yu & colleagues…
tinyurl.com/257dptx2
2
11
700
3 Jun 2025
What did I learn at #ASCO2025 ?
1. Increasing intensity of treatment improves PFS& toxicity- still need OS data for shared decision making
2. Powerful new treatments for #ProstateCancer are coming. get patients on trial
3. Get biomarkers on your #ProstateCancer
Thanks everyone!
1
9
148
Edwin Posadas, MD retweeted
3 Jun 2025
As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs
Did we lower standard to PFS when both agents are approved for mCRPC?
🤔
#ProstateCancer #ASCO25
nature.com/articles/s41585-0…
6
23
2,707
Edwin Posadas, MD retweeted
3 Jun 2025
Another proud @RadOncUH Chair moment to see our soon to be newest faculty @Soum_Roy_RadOnc being recognized for his statistical brilliance in collaboration with #IRONMAN #ASCO25 @ASCO
Way to go!
@JasonBrownMDPhD @PBarataMD @jeshoag @LPonsky @GUONCGarciaJA @TedTeknosMD @DanSimonMD
2
12
59
2,473
3 Jun 2025
Amazing what STAMPEDE has done for science: the US needs to do something this important for prostate cancer #ASCO25
2
1
18
1,164
3 Jun 2025
nice job by @MichaelOng_MD promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25
2
13
626
Edwin Posadas, MD retweeted
2 Jun 2025
Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? @DrChoueiri @nlinmd @DrKarenKnudsen @DrPaulNguyen @APDicker @EdwinPosadasMD @DrKatePedersen @JoshLangMD @PamelaKunzMD @fumikochino
5
8
93
5,985
Edwin Posadas, MD retweeted
2 Jun 2025
Another #ASCO25 happy dance. A celebration of friends, collaboration, and a common purpose to cure cancer.
7
10
169
15,699
3 Jun 2025
Great discussion from Angela Jia: contextualizing these 2 abstracts was key. Love the point of PSMA-PET and STAMPEDE when interpreting this data and contemporary RT approaches for localized PCA #ASCO25
2
243